Jupiter Neurosciences (NASDAQ:JUNS) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Jupiter Neurosciences (NASDAQ:JUNS) to a strong sell rating in a report published on Saturday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jupiter Neurosciences in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Jupiter Neurosciences Stock Up 4.1%

Shares of NASDAQ JUNS opened at $5.31 on Friday. The company has a market cap of $2.55 million, a price-to-earnings ratio of -0.26 and a beta of 1.99. The firm’s fifty day moving average is $14.06 and its 200 day moving average is $26.91. Jupiter Neurosciences has a 52 week low of $4.76 and a 52 week high of $137.96.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($4.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.75) by ($0.75). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.23 million.

Institutional Investors Weigh In On Jupiter Neurosciences

Several institutional investors and hedge funds have recently modified their holdings of JUNS. Vestor Capital LLC boosted its stake in shares of Jupiter Neurosciences by 144,607.2% during the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after purchasing an additional 970,314 shares in the last quarter. Geode Capital Management LLC raised its stake in Jupiter Neurosciences by 27.8% in the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after buying an additional 28,826 shares in the last quarter. Yorkville Advisors Global LP purchased a new stake in Jupiter Neurosciences in the fourth quarter worth about $135,000. Finally, Allen Capital Group LLC purchased a new stake in Jupiter Neurosciences in the fourth quarter worth about $31,000.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.